Multiple endocrine neoplasia type 1 overview: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
 
(12 intermediate revisions by 6 users not shown)
Line 2: Line 2:
{{Multiple endocrine neoplasia type 1}}
{{Multiple endocrine neoplasia type 1}}
{{CMG}}; {{AE}} {{Ammu}}
{{CMG}}; {{AE}} {{Ammu}}
==Overview==
==Overview==
Multiple endocrine neoplasia type 1 (MEN-1 syndrome) or Wermer's syndrome is part of a group of disorders that affect the [[endocrine system]] through development of neoplastic lesions in the [[pituitary]], the [[parathyroid]] gland and the [[pancreas]]. Multiple endocrine neoplasia type 1 was first described by Dr. Erdheim, a German physician, in 1903 by reporting a case of an [[acromegaly|acromegalic]] patient with [[pituitary adenoma]] and three enlarged [[parathyroid gland]]s. Development of multiple endocrine neoplasia type 1 is the result of multiple [[genetic mutation]]s of mainly ''MEN1'' [[gene]]. The [[pathophysiology]] of multiple endocrine neoplasia type 1 depends on the [[histological]] subtype. Common risk factors in the development of multiple endocrine neoplasia type 1 are family history, history of [[Zollinger-Ellison syndrome]] and [[pituitary disease|pituitary dysfunction]]. Biochemical tests and imaging techniques are used to screen for multiple endocrine neoplasia type 1. Symptoms of multiple endocrine neoplasia type 1 include [[lethargy]], [[depression]], [[oligomenorrhea]], [[constipation]], [[headache]] and [[diarrhea]]. [[MRI]] may be helpful in the [[diagnosis]] of multiple endocrine neoplasia type 1. Surgery is the mainstay of treatment for multiple endocrine neoplasia type 1.
Multiple endocrine neoplasia type 1 (MEN-1 syndrome) or Wermer's syndrome is part of a group of disorders that affect the [[endocrine system]] through development of neoplastic lesions in the [[pituitary]], the [[parathyroid]] gland and the [[pancreas]]. Multiple endocrine neoplasia type 1 was first described by Dr.Erdheim, a German physician, in 1903 by reporting a case of an [[acromegaly|acromegalic]] patient with [[pituitary adenoma]] and three enlarged [[parathyroid gland]]s. Development of multiple endocrine neoplasia type 1 is the result of multiple [[genetic mutation]]s of mainly ''MEN1'' [[gene]]. The [[pathophysiology]] of multiple endocrine neoplasia type 1 depends on the [[histological]] subtype. Common risk factors in the development of multiple endocrine neoplasia type 1 are family history, history of [[Zollinger-Ellison syndrome]] and [[pituitary disease|pituitary dysfunction]]. Symptoms of multiple endocrine neoplasia type 1 include lethargy, depression, oligomenorrhea, constipation, headache and diarrhea. Biochemical tests and imaging techniques are used to screen for multiple endocrine neoplasia type 1. Symptoms of multiple endocrine neoplasia type 1 include [[lethargy]], [[depression]], [[oligomenorrhea]], [[constipation]], [[headache]] and [[diarrhea]]. [[MRI]] may be helpful in the [[diagnosis]] of multiple endocrine neoplasia type 1. Surgery is the mainstay of treatment for multiple endocrine neoplasia type 1.
 
==Historical Perspective==
==Historical Perspective==
Multiple endocrine neoplasia type 1 was first described by Dr. Erdheim, a German physician, in 1903 by reporting a case of an [[acromegaly|acromegalic]] patient with [[pituitary adenoma]] and three enlarged [[parathyroid gland]]s.  
Multiple endocrine neoplasia type 1 was first described by Dr.Erdheim, a German physician, in 1903 by reporting a case of an [[acromegaly|acromegalic]] patient with [[pituitary adenoma]] and three enlarged [[parathyroid gland]]s.  
 
==Pathophysiology==
==Pathophysiology==
Development of multiple endocrine neoplasia type 1 is the result of multiple [[genetic mutation]]s. [[Gene]] involved in the [[pathogenesis]] of multiple endocrine neoplasia type 1 is ''MEN1'' [[gene]]. The [[pathophysiology]] of multiple endocrine neoplasia type 1 depends on the [[histological]] subtype.
Development of multiple endocrine neoplasia type 1 is the result of multiple [[genetic mutation]]s. [[Gene]] involved in the [[pathogenesis]] of multiple endocrine neoplasia type 1 is ''MEN1'' [[gene]]. The [[pathophysiology]] of multiple endocrine neoplasia type 1 depends on the [[histological]] subtype.


==Causes==
==Causes==
Multiple endocrine neoplasia type 1 is caused by a [[mutation]] in the ''MEN'' gene.
Multiple endocrine neoplasia type-1 occurs due to the [[mutations]] in [[gene]] MEN-1. This [[gene]] encodes for menin [[protein]]. Menin prevents the [[cells]] from growing and dividing aggressively. Menin is likely involved in cell functions such as copying and repairing [[DNA]] and regulating the activity of other [[genes]]. Inactivating [[mutations]] of both the copies of the MEN1 gene leads to lack of availability of menin to control [[cell growth]] and division. This leads to the formation of [[tumors]] characteristic of the MEN-1 syndrome. Why these tumors preferentially affect endocrine tissues is unclear.


==Differential Diagnosis==
==Differentiating Multiple endocrine neoplasia type 1 from Other Diseases==
Multiple endocrine neoplasia type 1 must be differentiated from other  hereditary diseases such as [[von Hippel-Lindau syndrome]], [[tuberous sclerosis]], [[carney complex]], [[neurofibromatosis type 1]], [[Li-Fraumeni syndrome]], [[multiple endocrine neoplasia type 2]], [[familial hyperparathyroidism]], [[pheochromocytoma]] and [[acromegaly]].
Multiple endocrine neoplasia type 1 must be differentiated from other  hereditary diseases such as [[von Hippel-Lindau syndrome]], [[tuberous sclerosis]], [[carney complex]], [[neurofibromatosis type 1]], [[Li-Fraumeni syndrome]], [[multiple endocrine neoplasia type 2]], familial hyperparathyroidism, [[pheochromocytoma]] and [[acromegaly]].


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The prevalence of multiple endocrine neoplasia type 1 is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop multiple endocrine neoplasia type 1, but it is commonly diagnosed among patients between 18-50 years of age. Multiple endocrine neoplasia type 1 affects men and women equally. There is no racial predilection to multiple endocrine neoplasia type 1.
The [[prevalence]] of multiple endocrine neoplasia type 1 is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop multiple endocrine neoplasia type 1, but it is commonly diagnosed among patients between 18-50 years of age. Multiple endocrine neoplasia type 1 affects men and women equally. There is no racial predilection to multiple endocrine neoplasia type 1.


==Risk Factors==
==Risk Factors==
Line 25: Line 28:


==Natural history, Complications and Prognosis==
==Natural history, Complications and Prognosis==
The manifestations of multiple endocrine neoplasia type 1 usually develop in the first, second or third decade of life and the age at which multiple endocrine neoplasia type 1 can begin to cause symptoms can vary from one family member to another. Depending on the extent of the [[tumor]] at the time of [[diagnosis]], the [[prognosis]] may varyHowever, the [[prognosis]] is generally regarded as good.
The natural history largely depends on the manifestation and virulence of the manifestations. The manifestations of multiple endocrine neoplasia type 1 usually develop in the first, second, or third decade of life. If left untreated, manifestations of multiple endocrine neoplasia type 1 may gradually worsen, and patients may die of complications of the disease. Life-threatening complications of multiple endocrine neoplasia type 1 include [[gastrointestinal bleeding]], [[convulsions]], [[hypokalemia]], [[hypoglycemia]], and [[venous thrombosis]]. Although many [[tumor]]s associated with multiple endocrine neoplasia type 1 are [[benign]], approximately half of people with multiple endocrine neoplasia type 1 eventually develop a cancerous [[tumor]].  The [[prognosis]] of multiple endocrine neoplasia type 1 is generally good with treatment. Development of pancreatic cancer is associated with poor prognosis.
 
==Diagnosis==
===Diagnosis Criteria===
There are no established criteria for the diagnosis of MEN 1.


==History and Symptoms==
===History and Symptoms===
Symptoms of multiple endocrine neoplasia type 1 include [[lethargy]], [[depression]], [[oligomenorrhea]], [[constipation]], [[headache]] and [[diarrhea]].
Symptoms of multiple endocrine neoplasia type 1 include [[lethargy]], [[depression]], [[oligomenorrhea]], [[constipation]], [[headache]] and [[diarrhea]].
==Physical Examination==
===Physical Examination===
Common physical examination findings of multiple endocrine neoplasia type 1 include [[rash]], lymphadenopathy, fever and abdominal mass.
Common physical examination findings of multiple endocrine neoplasia type 1 include [[rash]], [[lymphadenopathy]], fever and abdominal mass.


==Laboratory Findings==
===Laboratory Findings===
Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 1 include increased [[parathyroid hormone]], increased [[gastrin]], and increased [[cortisol]].
Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 1 include increased [[parathyroid hormone]], increased [[gastrin]], and increased [[cortisol]].
==Ultrasound==
 
===Ultrasound===
Abdominal [[ultrasound]] may be helpful in monitoring [[tumor]] growth and [[metastases]] in multiple endocrine neoplasia type 1.
Abdominal [[ultrasound]] may be helpful in monitoring [[tumor]] growth and [[metastases]] in multiple endocrine neoplasia type 1.


==CT==
===CT===
Abdominal [[CT]] scan may be helpful in the [[diagnosis]] of multiple endocrine neoplasia type 1. Findings on [[CT]] scan suggestive of multiple endocrine neoplasia type 1 include thickened [[stomach]] rugal folds, multiple gastric [[nodule]]s and calcified or cystic [[pancreatic tumor]]s.
Abdominal [[CT]] scan may be helpful in the [[diagnosis]] of multiple endocrine neoplasia type 1. Findings on [[CT]] scan suggestive of multiple endocrine neoplasia type 1 include thickened [[stomach]] rugal folds, multiple gastric [[nodule]]s and calcified or cystic [[pancreatic tumor]]s.


==MRI==
===MRI===
[[MRI]] may be helpful in the [[diagnosis]] of multiple endocrine neoplasia type 1. Findings on MRI suggestive of multiple endocrine neoplasia type 1 include diffuse heterogenous enhancement of T1 C+ (Gd), low T1 signal and high T2 signal.
[[MRI]] may be helpful in the [[diagnosis]] of multiple endocrine neoplasia type 1. Findings on MRI suggestive of multiple endocrine neoplasia type 1 include diffuse heterogenous enhancement of T1 C+ (Gd), low T1 signal and high T2 signal.


==Other Imaging Findings==
===Other Imaging Findings===
Other imaging studies for multiple endocrine neoplasia type 1 include fluoro-di-glucose-[[PET]]/[[CT]], [[venous sampling]], [[angiography]] and endovascular procedures, such as trans-arterial chemo-[[embolization]] (TACE).
Other imaging studies for multiple endocrine neoplasia type 1 include fluoro-di-glucose-[[PET]]/[[CT]], [[venous sampling]], [[angiography]] and endovascular procedures, such as trans-arterial chemo-[[embolization]] (TACE).


==Other Diagnostic Studies==
===Other Diagnostic Studies===
Other diagnostic studies for multiple endocrine neoplasia type 1 include [[genetic testing]], which demonstrates [[gene mutation]] in [[proband]] of ''MEN1'' gene.
Other diagnostic studies for multiple endocrine neoplasia type 1 include [[genetic testing]], which demonstrates [[gene mutation]] in [[proband]] of ''MEN1'' gene.


==Medical Therapy==
==Treatment==
Pharmacologic medical therapies for multiple endocrine neoplasia type 1  include [[cabergoline]], [[somatostatin]] analogues, and [[H2- receptor blocker]]s.
===Medical Therapy===
Pharmacologic medical therapies for multiple endocrine neoplasia type 1  include [[cabergoline]], [[somatostatin]] analogues, and [[H₂-receptor antagonist|H2-receptor blockers]].


==Surgery==
===Surgery===
Surgery is the mainstay of treatment for multiple endocrine neoplasia type 1.
Surgery is the mainstay of treatment for multiple endocrine neoplasia type 1.


==Secondary Prevention==
===Primary Prevention===
According to the National Caner Institute, surveillance for multiple endocrine neoplasia type 1 by imaging studies such as brain [[MRI]], abdominal [[CT]] and abdominal [[MRI]] is recommended every 3-5 year among patients with  [[pituitary tumor]]s and [[pancreatic neuroendocrine tumor]]s respectively. Biochemical tests such as serum [[prolactin]], [[insulin-like growth factor]] 1, fasting total serum [[calcium]], ionized [[calcium]], [[parathyroid hormone]], fasting serum [[gastrin]], [[chromogranin A]], pancreatic polypeptide, [[glucagon]] and vasointestinal polypeptide are recommended every year among patients with [[pituitary tumor]]s,  [[pancreatic neuroendocrine tumor]]s and [[primary hyperparathyroidism]].
There is no established method for prevention of Multiple endocrine neoplasia 1.
 
===Secondary Prevention===
According to the National Cancer Institute, surveillance for multiple endocrine neoplasia type 1 by imaging studies such as brain [[MRI]], abdominal [[CT]] and abdominal [[MRI]] is recommended every 3-5 year among patients with  [[pituitary tumor]]s and [[pancreatic neuroendocrine tumor]]s respectively. Biochemical tests such as serum [[prolactin]], [[insulin-like growth factor]] 1, fasting total serum [[calcium]], ionized [[calcium]], [[parathyroid hormone]], fasting serum [[gastrin]], [[chromogranin A]], pancreatic polypeptide, [[glucagon]] and vasointestinal polypeptide are recommended every year among patients with [[pituitary tumor]]s,  [[pancreatic neuroendocrine tumor]]s and [[primary hyperparathyroidism]].
 
===Future or Investigational therapies===
Future or investigational therapies of multiple endocrine neoplasia type 1 include [[TRK|TRK-inhibitors]] ([[tropomyosin]] receptor [[Kinase inhibitor|kinase inhibitors]]), [[mTOR]] inhibitors, thienopyrimidine analogs and molecular [[Phenotype|phenotyping]].
 
==References==
{{reflist|2}}


==Future or Investigational therapies==
[[Category:Oncology]]
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.
[[Category:Endocrinology]]
==Reference==
{{Reflist}}


[[Category:Hereditary cancers]]
{{WS}}
{{WH}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Surgery]]

Latest revision as of 02:45, 27 November 2017

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 overview

CDC on Multiple endocrine neoplasia type 1 overview

Multiple endocrine neoplasia type 1 overview in the news

Blogs on Multiple endocrine neoplasia type 1 overview

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Multiple endocrine neoplasia type 1 (MEN-1 syndrome) or Wermer's syndrome is part of a group of disorders that affect the endocrine system through development of neoplastic lesions in the pituitary, the parathyroid gland and the pancreas. Multiple endocrine neoplasia type 1 was first described by Dr.Erdheim, a German physician, in 1903 by reporting a case of an acromegalic patient with pituitary adenoma and three enlarged parathyroid glands. Development of multiple endocrine neoplasia type 1 is the result of multiple genetic mutations of mainly MEN1 gene. The pathophysiology of multiple endocrine neoplasia type 1 depends on the histological subtype. Common risk factors in the development of multiple endocrine neoplasia type 1 are family history, history of Zollinger-Ellison syndrome and pituitary dysfunction. Symptoms of multiple endocrine neoplasia type 1 include lethargy, depression, oligomenorrhea, constipation, headache and diarrhea. Biochemical tests and imaging techniques are used to screen for multiple endocrine neoplasia type 1. Symptoms of multiple endocrine neoplasia type 1 include lethargy, depression, oligomenorrhea, constipation, headache and diarrhea. MRI may be helpful in the diagnosis of multiple endocrine neoplasia type 1. Surgery is the mainstay of treatment for multiple endocrine neoplasia type 1.

Historical Perspective

Multiple endocrine neoplasia type 1 was first described by Dr.Erdheim, a German physician, in 1903 by reporting a case of an acromegalic patient with pituitary adenoma and three enlarged parathyroid glands.

Pathophysiology

Development of multiple endocrine neoplasia type 1 is the result of multiple genetic mutations. Gene involved in the pathogenesis of multiple endocrine neoplasia type 1 is MEN1 gene. The pathophysiology of multiple endocrine neoplasia type 1 depends on the histological subtype.

Causes

Multiple endocrine neoplasia type-1 occurs due to the mutations in gene MEN-1. This gene encodes for menin protein. Menin prevents the cells from growing and dividing aggressively. Menin is likely involved in cell functions such as copying and repairing DNA and regulating the activity of other genes. Inactivating mutations of both the copies of the MEN1 gene leads to lack of availability of menin to control cell growth and division. This leads to the formation of tumors characteristic of the MEN-1 syndrome. Why these tumors preferentially affect endocrine tissues is unclear.

Differentiating Multiple endocrine neoplasia type 1 from Other Diseases

Multiple endocrine neoplasia type 1 must be differentiated from other hereditary diseases such as von Hippel-Lindau syndrome, tuberous sclerosis, carney complex, neurofibromatosis type 1, Li-Fraumeni syndrome, multiple endocrine neoplasia type 2, familial hyperparathyroidism, pheochromocytoma and acromegaly.

Epidemiology and Demographics

The prevalence of multiple endocrine neoplasia type 1 is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop multiple endocrine neoplasia type 1, but it is commonly diagnosed among patients between 18-50 years of age. Multiple endocrine neoplasia type 1 affects men and women equally. There is no racial predilection to multiple endocrine neoplasia type 1.

Risk Factors

Common risk factors in the development of multiple endocrine neoplasia type 1 are family history, history of Zollinger-Ellison syndrome and pituitary dysfunction.

Screening

According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by imaging studies such as brain MRI, abdominal CT and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vasointestinal polypeptide are recommended every year among patients with pituitary tumors, pancreatic neuroendocrine tumors and primary hyperparathyroidism.

Natural history, Complications and Prognosis

The natural history largely depends on the manifestation and virulence of the manifestations. The manifestations of multiple endocrine neoplasia type 1 usually develop in the first, second, or third decade of life. If left untreated, manifestations of multiple endocrine neoplasia type 1 may gradually worsen, and patients may die of complications of the disease. Life-threatening complications of multiple endocrine neoplasia type 1 include gastrointestinal bleeding, convulsions, hypokalemia, hypoglycemia, and venous thrombosis. Although many tumors associated with multiple endocrine neoplasia type 1 are benign, approximately half of people with multiple endocrine neoplasia type 1 eventually develop a cancerous tumor. The prognosis of multiple endocrine neoplasia type 1 is generally good with treatment. Development of pancreatic cancer is associated with poor prognosis.

Diagnosis

Diagnosis Criteria

There are no established criteria for the diagnosis of MEN 1.

History and Symptoms

Symptoms of multiple endocrine neoplasia type 1 include lethargy, depression, oligomenorrhea, constipation, headache and diarrhea.

Physical Examination

Common physical examination findings of multiple endocrine neoplasia type 1 include rash, lymphadenopathy, fever and abdominal mass.

Laboratory Findings

Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 1 include increased parathyroid hormone, increased gastrin, and increased cortisol.

Ultrasound

Abdominal ultrasound may be helpful in monitoring tumor growth and metastases in multiple endocrine neoplasia type 1.

CT

Abdominal CT scan may be helpful in the diagnosis of multiple endocrine neoplasia type 1. Findings on CT scan suggestive of multiple endocrine neoplasia type 1 include thickened stomach rugal folds, multiple gastric nodules and calcified or cystic pancreatic tumors.

MRI

MRI may be helpful in the diagnosis of multiple endocrine neoplasia type 1. Findings on MRI suggestive of multiple endocrine neoplasia type 1 include diffuse heterogenous enhancement of T1 C+ (Gd), low T1 signal and high T2 signal.

Other Imaging Findings

Other imaging studies for multiple endocrine neoplasia type 1 include fluoro-di-glucose-PET/CT, venous sampling, angiography and endovascular procedures, such as trans-arterial chemo-embolization (TACE).

Other Diagnostic Studies

Other diagnostic studies for multiple endocrine neoplasia type 1 include genetic testing, which demonstrates gene mutation in proband of MEN1 gene.

Treatment

Medical Therapy

Pharmacologic medical therapies for multiple endocrine neoplasia type 1 include cabergoline, somatostatin analogues, and H2-receptor blockers.

Surgery

Surgery is the mainstay of treatment for multiple endocrine neoplasia type 1.

Primary Prevention

There is no established method for prevention of Multiple endocrine neoplasia 1.

Secondary Prevention

According to the National Cancer Institute, surveillance for multiple endocrine neoplasia type 1 by imaging studies such as brain MRI, abdominal CT and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vasointestinal polypeptide are recommended every year among patients with pituitary tumors, pancreatic neuroendocrine tumors and primary hyperparathyroidism.

Future or Investigational therapies

Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK-inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.

References

Template:WS Template:WH